BACKGROUND: Interruption of a non-nucleoside reverse transcriptase inhibitor (NNRTI)-regimen is often necessary, but must be performed with caution because NNRTIs have a low genetic barrier to resistance. Limited data exist to guide clinical practice on the best interruption strategy to use. METHODS: Patients in the drug-conservation arm of the Strategies for Management of Antiretroviral Therapy (SMART) trial who interrupted a fully suppressive NNRTI-regimen were evaluated. From 2003, SMART recommended interruption of an NNRTI by a staggered interruption, in which the NNRTI was stopped before the NRTIs, or by replacing the NNRTI with another drug before interruption. Simultaneous interruption of all antiretrovirals was discouraged. Resuppression rates 4-8 months after reinitiating NNRTI-therapy were assessed, as was the detection of drug-resistance mutations within 2 months of the treatment interruption in a subset (N = 141). RESULTS: Overall, 601/688 (87.4%) patients who restarted an NNRTI achieved viral resuppression. The adjusted odds ratio (95% confidence interval) for achieving resuppression was 1.94 (1.02-3.69) for patients with a staggered interruption and 3.64 (1.37-9.64) for those with a switched interruption compared with patients with a simultaneous interruption. At least one NNRTI-mutation was detected in the virus of 16.4% patients with simultaneous interruption, 12.5% patients with staggered interruption and 4.2% patients with switched interruption. Fewer patients with detectable mutations (i.e. 69.2%) achieved HIV-RNA of 400 copies/ml or less compared with those in whom no mutations were detected (i.e. 86.7%; P = 0.05). CONCLUSION: In patients who interrupt a suppressive NNRTI-regimen, the choice of interruption strategy may influence resuppression rates when restarting a similar regimen. NNRTI drug-resistance mutations were observed in a relatively high proportion of patients. These data provide additional support for a staggered or switched interruption strategy for NNRTI drugs.
BACKGROUND: Interruption of a non-nucleoside reverse transcriptase inhibitor (NNRTI)-regimen is often necessary, but must be performed with caution because NNRTIs have a low genetic barrier to resistance. Limited data exist to guide clinical practice on the best interruption strategy to use. METHODS: Patients in the drug-conservation arm of the Strategies for Management of Antiretroviral Therapy (SMART) trial who interrupted a fully suppressive NNRTI-regimen were evaluated. From 2003, SMART recommended interruption of an NNRTI by a staggered interruption, in which the NNRTI was stopped before the NRTIs, or by replacing the NNRTI with another drug before interruption. Simultaneous interruption of all antiretrovirals was discouraged. Resuppression rates 4-8 months after reinitiating NNRTI-therapy were assessed, as was the detection of drug-resistance mutations within 2 months of the treatment interruption in a subset (N = 141). RESULTS: Overall, 601/688 (87.4%) patients who restarted an NNRTI achieved viral resuppression. The adjusted odds ratio (95% confidence interval) for achieving resuppression was 1.94 (1.02-3.69) for patients with a staggered interruption and 3.64 (1.37-9.64) for those with a switched interruption compared with patients with a simultaneous interruption. At least one NNRTI-mutation was detected in the virus of 16.4% patients with simultaneous interruption, 12.5% patients with staggered interruption and 4.2% patients with switched interruption. Fewer patients with detectable mutations (i.e. 69.2%) achieved HIV-RNA of 400 copies/ml or less compared with those in whom no mutations were detected (i.e. 86.7%; P = 0.05). CONCLUSION: In patients who interrupt a suppressive NNRTI-regimen, the choice of interruption strategy may influence resuppression rates when restarting a similar regimen. NNRTI drug-resistance mutations were observed in a relatively high proportion of patients. These data provide additional support for a staggered or switched interruption strategy for NNRTI drugs.
Authors: Heather J Ribaudo; David W Haas; Camlin Tierney; Richard B Kim; Grant R Wilkinson; Roy M Gulick; David B Clifford; Catia Marzolini; Courtney V Fletcher; Karen T Tashima; Daniel R Kuritzkes; Edward P Acosta Journal: Clin Infect Dis Date: 2005-12-27 Impact factor: 9.079
Authors: Sarah Palmer; Valerie Boltz; Frank Maldarelli; Mary Kearney; Elias K Halvas; Diane Rock; Judith Falloon; Richard T Davey; Robin L Dewar; Julia A Metcalf; John W Mellors; John M Coffin Journal: AIDS Date: 2006-03-21 Impact factor: 4.177
Authors: Javier Martinez-Picado; Kristina Morales-Lopetegi; Terri Wrin; Julia G Prado; Simon D W Frost; Christos J Petropoulos; Bonaventura Clotet; Lidia Ruiz Journal: AIDS Date: 2002-04-12 Impact factor: 4.177
Authors: D Hawkins; M Blott; P Clayden; A de Ruiter; G Foster; C Gilling-Smith; B Gosrani; H Lyall; D Mercey; M-L Newell; S O'Shea; R Smith; J Sunderland; C Wood; G Taylor Journal: HIV Med Date: 2005-07 Impact factor: 3.180
Authors: M Arnedo-Valero; F Garcia; C Gil; T Guila; E Fumero; P Castro; J L Blanco; J M Miró; T Pumarola; J M Gatell Journal: Clin Infect Dis Date: 2005-08-04 Impact factor: 9.079
Authors: Lucia Palmisano; Marina Giuliano; Raffaella Bucciardini; Vincenzo Fragola; Mauro Andreotti; Clementina Galluzzo; Maria F Pirillo; Liliana E Weimer; Romano Arcieri; Elena A P Germinario; Roberta Amici; Maria Grazia Mancini; Antonella d'Arminio Monforte; Francesco Castelli; Pietro Caramello; Stefano Vella Journal: J Acquir Immune Defic Syndr Date: 2007-09-01 Impact factor: 3.731
Authors: Karin J Metzner; Sebastian Bonhoeffer; Marek Fischer; Rose Karanicolas; Kristina Allers; Beda Joos; Rainer Weber; Bernard Hirschel; Leondios G Kostrikis; Huldrych F Günthard Journal: J Infect Dis Date: 2003-11-03 Impact factor: 5.226
Authors: A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch Journal: HIV Med Date: 2015-02-03 Impact factor: 3.180
Authors: Christopher J Hoffmann; Salome Charalambous; Alison D Grant; Lynn Morris; Gavin J Churchyard; Richard E Chaisson Journal: Trop Med Int Health Date: 2014-02 Impact factor: 2.622
Authors: Awachana Jiamsakul; Stephen J Kerr; Oon Tek Ng; Man Po Lee; Romanee Chaiwarith; Evy Yunihastuti; Kinh Van Nguyen; Thuy Thanh Pham; Sasisopin Kiertiburanakul; Rossana Ditangco; Vonthanak Saphonn; Benedict L H Sim; Tuti Parwati Merati; Wingwai Wong; Pacharee Kantipong; Fujie Zhang; Jun Yong Choi; Sanjay Pujari; Adeeba Kamarulzaman; Shinichi Oka; Mahiran Mustafa; Winai Ratanasuwan; Boondarika Petersen; Matthew Law; Nagalingeswaran Kumarasamy Journal: Trop Med Int Health Date: 2016-03-29 Impact factor: 2.622
Authors: Steven J Reynolds; Cissy Kityo; Claire W Hallahan; Geoffrey Kabuye; Diana Atwiine; Frank Mbamanya; Francis Ssali; Robin Dewar; Marybeth Daucher; Richard T Davey; Peter Mugyenyi; Anthony S Fauci; Thomas C Quinn; Mark R Dybul Journal: PLoS One Date: 2010-04-22 Impact factor: 3.240
Authors: Ennio Polilli; Giustino Parruti; Luana Cosentino; Federica Sozio; Annalisa Saracino; Augusta Consorte; Gioacchino Angarano; Francesco Di Masi; Elena Mazzotta; Paolo Fazii Journal: J Med Case Rep Date: 2009-09-18